Effect of transarterial chemoembolization with miriplatin plus epirubicin on local control of hepatocellular carcinoma: a retrospective comparison with miriplatin monotherapy

{"sci_version": "1.0", "schema": "https://corpus.bntrg.co.uk/sci/1.0/sci.schema.json", "id": "pmid:23986641", "kind": "science-record", "revision": 1, "content_hash": "sha256:19cbb78b75aaad9b27ead715c91df850a07271620bb3a2dc5c22adba72e6c751", "created_at": "2026-11-01T10:25:48Z", "updated_at": "2026-11-01T10:25:48Z", "generator": {"name": "corpus-assay-engine", "converter": "sep_to_sci_v1", "source_package_schema": "urn:bntrg:sep:1.0.0"}, "paper": {"state": "partial", "title": "Effect of transarterial chemoembolization with miriplatin plus epirubicin on local control of hepatocellular carcinoma: a retrospective comparison with miriplatin monotherapy", "doi": "10.2147/OTT.S49443", "pmid": "23986641", "authors": null, "journal": "OncoTargets and therapy", "year": 2013, "abstract": null, "claims": [{"id": "claim-1", "statement": "the 1-year local tumour control rate for transarterial chemoembolisation with miriplatin plus low-dose epirubicin, against miriplatin alone", "kind": "quantitative", "state": "complete", "target": {"value": 65.0, "unit": "percent", "tolerance": null, "source": "chars 953-1123 of source sha256 4fd3e39c33eda037be809b2256c55f605b7e06a55f62bba451fbe99ebc431d27"}, "evidence": [{"asset": "source:pmid:23986641", "locator": "chars 953-1123 of source sha256 4fd3e39c33eda037be809b2256c55f605b7e06a55f62bba451fbe99ebc431d27", "quote": "The local control rates at 6 months and 1 year were 87% and 65% for the miriplatin plus low-dose epirubicin group, and 61% and 43% for the miriplatin group, respectively."}]}], "gaps": ["abstract", "authors"]}, "experiment": {"state": "partial", "objective": "the 1-year local tumour control rate for transarterial chemoembolisation with miriplatin plus low-dose epirubicin, against miriplatin alone", "steps": [{"id": "read_published_estimate", "order": 1, "name": "Read the published estimate and its interval from the source", "kind": "other", "state": "complete", "blocked_on": null, "description": "The number a replication must land on, and the sentence it came from.", "duration_hours": null, "parameters": {}, "inputs": ["source:pmid:23986641"], "outputs": ["the published estimate, its unit and its interval"], "instruments": [], "reagents": []}, {"id": "obtain_source_data", "order": 2, "name": "Obtain the source data behind the published result", "kind": "data-preparation", "state": "blocked", "blocked_on": "data:accession_absent", "description": "The published result cannot be recomputed without the data the paper analysed.", "duration_hours": null, "parameters": {}, "inputs": [], "outputs": ["the source data with its provenance"], "instruments": [], "reagents": []}, {"id": "run_analysis", "order": 3, "name": "Run the analysis programme", "kind": "analysis", "state": "blocked", "blocked_on": "method:epidemiological_modelling_incidence_rate", "description": "Re-run the paper's analysis on the source data and produce the registered result.", "duration_hours": null, "parameters": {}, "inputs": ["materials:the source data behind the published result in pmid:23986641"], "outputs": ["the registered result"], "instruments": [], "reagents": []}, {"id": "provide_capability_bench_workcell", "order": 4, "name": "Provide General bench workcell (liquid transfer, plate handling, incubation)", "kind": "computational", "state": "blocked", "blocked_on": "instrument not yet purchased", "description": "Make this capability available to the experiment: amplicon_seq, animal_model, apoptosis_assay, cell_culture, cell_imaging, chip_seq, clinical_cohort, clinical_trial, elisa, flow_cytometry, ihc, image_quantification, mass_spectrometry, methylation_array, microarray, qpcr, rna_seq, transfection, western_blot", "duration_hours": null, "parameters": {}, "inputs": [], "outputs": [], "instruments": [], "reagents": []}], "materials": ["the source data behind the published result in pmid:23986641", "the analysis programme that recomputes the published estimate"], "instruments": [], "reagents": [], "conditions": {}, "gaps": ["step:obtain_source_data blocked on data:accession_absent", "step:provide_capability_bench_workcell blocked on instrument not yet purchased", "step:run_analysis blocked on method:epidemiological_modelling_incidence_rate"]}, "data": {"state": "partial", "assets": [{"id": "source:pmid:23986641", "role": "manuscript", "format": "xml", "media_type": "application/xml", "uri": "https://doi.org/10.2147/OTT.S49443", "sha256": "sha256:4fd3e39c33eda037be809b2256c55f605b7e06a55f62bba451fbe99ebc431d27", "bytes": null, "access": "open", "state": "resolved", "reader": null, "reader_status": "reader_required", "identifier": "10.2147/OTT.S49443", "version": null, "note": "Source read by the package builder: full_text.", "structure": {"access_state": "full_text"}}, {"id": "materials:the source data behind the published result in pmid:23986641", "role": "raw", "format": "unknown", "media_type": "application/octet-stream", "uri": null, "sha256": null, "bytes": null, "access": "unknown", "state": "unavailable", "reader": null, "reader_status": "unknown", "identifier": null, "version": null, "note": "the source data behind the published result in pmid:23986641", "structure": {"material_kind": "dataset", "access_state": "not_identified"}}, {"id": "materials:the analysis programme that recomputes the published estimate", "role": "code", "format": "unknown", "media_type": "application/octet-stream", "uri": null, "sha256": null, "bytes": null, "access": "unknown", "state": "unavailable", "reader": null, "reader_status": "unknown", "identifier": null, "version": null, "note": "the analysis programme that recomputes the published estimate", "structure": {"material_kind": "code", "access_state": "absent"}}], "gaps": ["asset:materials:the analysis programme that recomputes the published estimate not verified", "asset:materials:the source data behind the published result in pmid:23986641 not verified", "asset:source:pmid:23986641 not verified"]}, "analysis": {"state": "partial", "methods": [{"id": "method-1", "family": "survival_analysis", "specific": "log-rank", "label": "Survival analysis", "dsl_operations": ["glm_logit_fit", "logrank_test", "survival_km"], "missing_operations": [], "expressible": true, "parameters": {}, "data_shapes": ["time_to_event_with_censoring"], "evidence": {"score": 0.7, "band": "medium", "quote": "We retrospectively analyzed the records of patients who underwent TACE using miriplatin plus low-dose epirubicin (30 patients, 61 nodules, August 2011–March 2012) and control patients who underwent TACE using miriplatin alone (36 patients, 70 nodules, June 2010–July 2011). The local control rate was compared between the two groups using the Kaplan–Meier estimator and the log-rank test. Factors affecting local tumor recurrence were analyzed using multivariate logistic regression analysis. Treatment-related toxicity was evaluated using the Common Terminology Criteria for Adverse Events."}}], "targets": [{"id": "target-1", "claim_id": "claim-1", "operation": null, "expected_value": 65.0, "unit": "percent", "tolerance": null, "state": "complete"}], "gaps": []}, "capability": {"state": "partial", "requirements": [{"capability_id": "capability:computational_analysis", "label": "Computational analysis platform", "assay_families": ["differential_expression", "gwas", "machine_learning", "meta_analysis", "molecular_docking", "network_analysis", "pca", "statistical_regression", "survival_analysis"], "availability_state": "owned", "tier_unlocked": "R1", "candidate": "Automated Assays Laravel application and simulated adapters"}, {"capability_id": "capability:bench_workcell", "label": "General bench workcell (liquid transfer, plate handling, incubation)", "assay_families": ["amplicon_seq", "animal_model", "apoptosis_assay", "cell_culture", "cell_imaging", "chip_seq", "clinical_cohort", "clinical_trial", "elisa", "flow_cytometry", "ihc", "image_quantification", "mass_spectrometry", "methylation_array", "microarray", "qpcr", "rna_seq", "transfection", "western_blot"], "availability_state": "purchasable", "tier_unlocked": "R3", "candidate": "Supplier-neutral 96/384-well liquid handler"}, {"capability_id": "capability:clinical_intervention", "label": "Clinical intervention and patient cohort access", "assay_families": ["clinical_trial", "clinical_cohort"], "availability_state": "unavailable", "tier_unlocked": "R4", "candidate": null}], "gaps": ["capability:capability:bench_workcell purchasable", "capability:capability:clinical_intervention unavailable"]}, "readiness": {"state": "blocked", "tier": "R4", "blocking_axis": "capability", "blocked_on": "capability:clinical_intervention", "axes": {"method": {"axis": "method", "tier": "R1", "blocker": null, "detail": {"outcome": "determined", "family": "survival_analysis", "specific_method": "kaplan_meier", "required_operations": ["glm_logit_fit", "logrank_test", "survival_km"], "basis": "Every DSL operation this method needs already exists."}}, "capability": {"axis": "capability", "tier": "R4", "blocker": "capability:clinical_intervention", "detail": {"families": ["clinical_cohort"], "capability_id": "capability:clinical_intervention", "availability_state": "unavailable", "considered": [{"family": "clinical_cohort", "capability_id": "capability:bench_workcell", "availability_state": "purchasable", "tier_unlocked": "R3"}, {"family": "clinical_cohort", "capability_id": "capability:clinical_intervention", "availability_state": "unavailable", "tier_unlocked": "R4"}], "basis": "The equipment register names no clinical capability at any gate. Patient data and clinical interventions need consent, ethics and a site, which is a collaboration rather than a purchase."}}, "data": {"axis": "data", "tier": "R4", "blocker": "data:accession_absent", "detail": {"applies": true, "reachable": false, "basis": "The record names no repository accession and no data-availability statement, so the source data has to be requested from the authors."}}}, "can_run": {"dsl_operations": ["glm_logit_fit", "logrank_test", "survival_km"], "assets": ["source:pmid:23986641"], "steps": ["read_published_estimate"]}, "must_build": {"dsl_operations": [], "converters": [], "readers": ["unknown", "xml"], "capabilities": ["capability:bench_workcell", "capability:clinical_intervention"], "data_gaps": ["source:pmid:23986641", "materials:the source data behind the published result in pmid:23986641", "materials:the analysis programme that recomputes the published estimate"]}, "gaps": ["capability:clinical_intervention"]}, "review": {"state": "partial", "machine_critique": {"status": "passed", "providers": [{"provider": "minimax-m3-1-flash", "model": "MiniMax-M3.1-Flash", "prompt_version": "peer-review-reading-v1", "prompt_hash": "f62c8e2b36815966416c568d62c7c438b269400c141c233533f4dd9c84c976d5", "source_hash": "4fd3e39c33eda037be809b2256c55f605b7e06a55f62bba451fbe99ebc431d27", "raw_response_sha256": "sha256:5cafd9527f8f7680f599239d73f66d950af9b17dfa530894767a4f93ae831f4c", "raw_response_chars": 1599}, {"provider": "minimax-m3", "model": "MiniMax-M3", "prompt_version": "peer-review-reading-v1", "prompt_hash": "b14ed901b6535c976329fbd9346c47c4269092673ca14dd90c0b560d664deb6d", "source_hash": "4fd3e39c33eda037be809b2256c55f605b7e06a55f62bba451fbe99ebc431d27", "raw_response_sha256": "sha256:a3c8a587b70498f8994b6c169cfdcb386447414d626be9c9cecbeee9d16f6625", "raw_response_chars": 3280}], "target_providers": [{"provider": "minimax-m3-1-flash", "model": "MiniMax-M3.1-Flash", "prompt_version": "replication-target-v2", "prompt_hash": "8310022d052d9f7cb10911ab674c501315fa7b6202df7134f9b09eeddb5881b9", "source_hash": "4fd3e39c33eda037be809b2256c55f605b7e06a55f62bba451fbe99ebc431d27", "raw_response": "{\"parent_value\":65,\"unit\":\"%\",\"evidence\":\"The local control rates at 6 months and 1 year were 87% and 65% for the miriplatin plus low-dose epirubicin group, and 61% and 43% for the miriplatin group, respectively.\",\"target_result\":\"65%\",\"number_stated\":true}", "reading": {"parent_value": 65, "unit": "%", "evidence": "The local control rates at 6 months and 1 year were 87% and 65% for the miriplatin plus low-dose epirubicin group, and 61% and 43% for the miriplatin group, respectively.", "target_result": "65%", "number_stated": true, "source_locator": "chars 953-1123 of source sha256 4fd3e39c33eda037be809b2256c55f605b7e06a55f62bba451fbe99ebc431d27"}, "recorded_at": "2026-10-31T14:30:31.250814+00:00"}, {"provider": "minimax-m3", "model": "MiniMax-M3", "prompt_version": "replication-target-v2", "prompt_hash": "7cfcb1e963bef52213043816f80f2f12547d16eab706b77875c3afb1bcab03ef", "source_hash": "4fd3e39c33eda037be809b2256c55f605b7e06a55f62bba451fbe99ebc431d27", "raw_response": "{\n  \"parent_value\": 65,\n  \"unit\": \"%\",\n  \"evidence\": \"The local control rates at 6 months and 1 year were 87% and 65% for the miriplatin plus low-dose epirubicin group, and 61% and 43% for the miriplatin group, respectively.\",\n  \"target_result\": \"The 1-year local tumour control rate for transarterial chemoembolisation with miriplatin plus low-dose epirubicin was 65%.\",\n  \"number_stated\": true\n}", "reading": {"parent_value": 65, "unit": "%", "evidence": "The local control rates at 6 months and 1 year were 87% and 65% for the miriplatin plus low-dose epirubicin group, and 61% and 43% for the miriplatin group, respectively.", "target_result": "The 1-year local tumour control rate for transarterial chemoembolisation with miriplatin plus low-dose epirubicin was 65%.", "number_stated": true, "source_locator": "chars 953-1123 of source sha256 4fd3e39c33eda037be809b2256c55f605b7e06a55f62bba451fbe99ebc431d27"}, "recorded_at": "2026-10-31T14:30:45.798721+00:00"}], "agreement": true, "disagreements": {"target_result": {"minimax-m3-1-flash": "At 1 year, the local tumour control rate was 65% for transarterial chemoembolisation with miriplatin plus low-dose epirubicin, compared with 43% for miriplatin alone.", "minimax-m3": "At 1 year, the local tumor control rate was 65% for TACE with miriplatin plus low-dose epirubicin versus 43% for TACE with miriplatin alone. The reported overall comparison favored the combination group (P = 0.038).", "decisive": false}, "physical_methods": {"minimax-m3-1-flash": ["Transarterial chemoembolisation with miriplatin plus low-dose epirubicin or miriplatin alone", "Dynamic contrast-enhanced CT or MRI every 1–3 months after TACE to assess local recurrence"], "minimax-m3": [], "decisive": false}, "analysis_methods": {"minimax-m3-1-flash": ["Kaplan–Meier estimator", "Log-rank test", "Multivariate Cox proportional hazards model with backward stepwise selection"], "minimax-m3": ["Kaplan–Meier estimator", "log-rank test", "univariate and multivariate analyses of local tumor recurrence", "Cox proportional hazards model with backward stepwise selection"], "decisive": false}, "source_claims": {"minimax-m3-1-flash": ["The local control rates at 6 months and 1 year were 87% and 65% for the miriplatin plus low-dose epirubicin group, and 61% and 43% for the miriplatin group, respectively.", "Local tumor control rates were significantly better in the miriplatin plus low-dose epirubicin group than in the miriplatin group (P = 0.038).", "Multivariate analysis showed that the addition of epirubicin was an independent factor associated with better local tumor control (hazard ratio 0.2, P = 0.001)."], "minimax-m3": ["The study retrospectively compared 30 patients with 61 nodules treated with miriplatin plus low-dose epirubicin against 36 patients with 70 nodules treated with miriplatin alone during different calendar periods.", "The local tumor control rates at 6 months and 1 year were 87% and 65% for the miriplatin plus low-dose epirubicin group and 61% and 43% for the miriplatin group, respectively.", "Local tumor control was significantly better in the miriplatin plus low-dose epirubicin group than in the miriplatin group (P = 0.038).", "In multivariate analysis, addition of epirubicin was an independent factor associated with better local tumor control (hazard ratio 0.2, P = 0.001).", "Median follow-up was 279.5 days for the miriplatin group and 294 days for the miriplatin plus epirubicin group.", "The authors noted possible selection and information bias, lack of histological confirmation, small sample size, more distal chemoembolization in the combination group, and a relatively short observation period for the combination group."], "decisive": false}}, "agreement_basis": {"policy": "decisive_fields", "decisive_fields": ["number_stated", "parent_value", "unit", "work_type"], "advisory_fields": ["analysis_methods", "physical_methods", "source_claims", "target_result"]}, "blinded": true}, "human_critique": {"status": "not_run", "reviewer": null, "signed_at": null, "conflict_checked": false, "commentary": null}, "stages": [{"key": "target_materials", "status": "pending", "reason": null, "evidence": null}, {"key": "independent_readings", "status": "passed", "reason": null, "evidence": {"provider_errors": []}}, {"key": "source_resolution", "status": "pending", "reason": null, "evidence": null}, {"key": "protocol_reconstruction", "status": "pending", "reason": null, "evidence": null}, {"key": "control_execution", "status": "pending", "reason": null, "evidence": null}, {"key": "control_comparison", "status": "pending", "reason": null, "evidence": null}, {"key": "publication", "status": "pending", "reason": null, "evidence": null}], "gaps": ["review.human_critique", "review.machine_critique.passed"]}, "execution": {"state": "absent", "status": "not_run", "mode": null, "runs": [], "gaps": ["execution.not_run"]}, "provenance": {"entities": [{"id": "package:8deee153412223468a646ba5a794d50c9ce0eaa9a068a57080bd0b787173a811", "type": "sep_package", "label": "SEP v1 package for pmid:23986641"}], "activities": [{"id": "activity:conversion:pmid:23986641", "type": "conversion", "used": ["package:8deee153412223468a646ba5a794d50c9ce0eaa9a068a57080bd0b787173a811"], "agent": "agent:corpus-assay-engine"}], "agents": [{"id": "agent:minimax-m3", "type": "model", "label": "minimax-m3"}, {"id": "agent:minimax-m3-1-flash", "type": "model", "label": "minimax-m3-1-flash"}, {"id": "agent:corpus-assay-engine", "type": "software", "label": "Corpus assay engine"}], "source_run_id": "run-20261023T122449232913", "dsl_catalogue_fingerprint": "343fb30756ba6ec3", "capability_table_fingerprint": "2cb3e42f047d2ecf", "snapshot_id": "ba34b49490d9bfaf"}, "lineage": {"parent_id": "cc289864-6cdd-4e1d-8b96-1b2539189d7d", "parent_hash": "8deee153412223468a646ba5a794d50c9ce0eaa9a068a57080bd0b787173a811", "fork_of": null, "generation": 1}, "gaps": ["abstract", "asset:materials:the analysis programme that recomputes the published estimate not verified", "asset:materials:the source data behind the published result in pmid:23986641 not verified", "asset:source:pmid:23986641 not verified", "authors", "capability:capability:bench_workcell purchasable", "capability:capability:clinical_intervention unavailable", "capability:clinical_intervention", "execution.not_run", "review.human_critique", "review.machine_critique.passed", "step:obtain_source_data blocked on data:accession_absent", "step:provide_capability_bench_workcell blocked on instrument not yet purchased", "step:run_analysis blocked on method:epidemiological_modelling_incidence_rate"]}